B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors
Open Access
- 1 March 2018
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 26 (3) , 695-707
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute/NIH (R01CA213131, P50CA107399, P30CA033572)
- STOP-CANCER Foundation
This publication has 55 references indexed in Scilit:
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumorsJournal of Clinical Investigation, 2013
- Coordinated regulation of myeloid cells by tumoursNature Reviews Immunology, 2012
- Presentation of Soluble Antigens to CD8+ T Cells by CpG Oligodeoxynucleotide-Primed Human Naive B CellsThe Journal of Immunology, 2011
- Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphomaHaematologica, 2010
- In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responsesNature Biotechnology, 2009
- Toll-like Receptor 9 Activation of Signal Transducer and Activator of Transcription 3 Constrains Its Agonist-Based ImmunotherapyCancer Research, 2009
- Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphomaBlood, 2008
- Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomasBlood, 2008
- Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironmentNature Reviews Immunology, 2007
- Toll-like receptor control of the adaptive immune responsesNature Immunology, 2004